Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews · Lung Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 100%Moderate 0 · 0%High 0 · 0%

ALK inhibitor vs any cytotoxic chemotherapy

Grade 5 adverse events (excluding progressive disease) · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer

ALK inhibitor showed no clear difference in grade 5 adverse events (excluding progressive disease) compared with any cytotoxic chemotherapy (low certainty).

1 finding from 1 review

Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer 2022 · Cochrane Headline outcomes only
RR 2.03 [0.89, 4.66]
6 studies · 1611 participants
Low

Next‐generation ALK inhibitor vs crizotinib

Grade 5 adverse events (excluding progressive disease) · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer

Next‐generation ALK inhibitor showed no clear difference in grade 5 adverse events (excluding progressive disease) compared with crizotinib (low certainty).

1 finding from 1 review

Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer 2022 · Cochrane Headline outcomes only
RR 0.85 [0.49, 1.47]
5 studies · 1263 participants
Low